crizotinib activity in a MET positive/ALK negative patient

[Olga]

This is a very interesting article - a new crizotinib report an NSCLC patient with the MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating its strong action as a MET inhibitor:

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification.
http://www.ncbi.nlm.nih.gov/pubmed/21623265

My comment:
I see the importance of this report because the high expression of MET in ASPS may support the potential role of targeted agents against MET. Recent study from China has shown 75% MET positivity in ASPS tumors (6 of 8 analyzed samples) http://www.ncbi.nlm.nih.gov/pubmed/19472090